Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes | |
OMIM | 540000 |
---|---|
DiseasesDB | 8254 |
MeSH | D017241 |
Overview
Mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like episodes, abbreviated to MELAS is one of the family of mitochondrial cytopathies, which also include MERRF, and Leber's Hereditary Optic Atrophy. [1] A feature of these diseases is that they are caused by defects in the mitochondrial genome which is inherited purely from the female parent. The disease can manifest in both sexes. [2]
Historical Perspective
Pathophysiology
Genetics
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes is a condition related to changes in mitochondrial DNA. Mutations in the MT-ND1, MT-ND5, MT-TH, MT-TL1, and MT-TV genes cause mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. The genes associated with MELAS are contained in mitochondrial DNA. Some of the genes related to MELAS provide instructions for making proteins involved in normal mitochondrial function. These proteins are part of a large enzyme complex in mitochondria that helps convert oxygen and simple sugars to energy. Other genes associated with this disorder provide instructions for making molecules called transfer RNAs (tRNAs), which are chemical cousins of DNA. These molecules help assemble protein building blocks called amino acids into full-length, functioning proteins within mitochondria.
Mutations in a particular transfer RNA gene, MT-TL1, cause more than 80 percent of all cases of MELAS. These mutations impair the ability of mitochondria to make proteins, use oxygen, and produce energy. Researchers have not determined how changes in mitochondrial DNA lead to the specific signs and symptoms of MELAS. They continue to investigate the effects of mitochondrial gene mutations in different tissues, particularly in the brain.[3]
This condition is inherited in a mitochondrial pattern, which is also known as maternal inheritance. This pattern of inheritance applies to genes contained in mitochondrial DNA. Because egg cells, but not sperm cells, contribute mitochondria to the developing embryo, only females pass mitochondrial conditions to their children. Mitochondrial disorders can appear in every generation of a family and can affect both males and females, but fathers do not pass mitochondrial traits to their children. In most cases, people with MELAS inherit an altered mitochondrial gene from their mother. Less commonly, the disorder results from a new mutation in a mitochondrial gene and occurs in people with no family history of MELAS.
Causes
Differentiating Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes from Other Diseases
Epidemiology and Demographics
MELAS is recognized as one of the most common mitochondrial disorders, affecting approximately 1 in every 4000 individuals.[4] While both sexes are equally susceptible to developing the condition, only females can transmit MELAS due to the unique nature of mitochondrial inheritance. Mitochondria are carried within the tails of sperm cells, which are shed outside the zygote during fertilization and are therefore not transmitted, resulting in this gender-specific inheritance pattern. Notably, there is no discernible racial preference associated with MELAS.[5]
Risk Factors
Screening
Natural History, Complications and Prognosis
Prognosis
There is no known treatment for the underlying disease, which is progressive and fatal. Patients are managed according to what areas of the body are affected at a particular time. Antioxidants and vitamins have been used, but there have been no consistent successes reported.
Diagnosis
Diagnosis Criteria
History and Symptoms
MELAS is a condition that affects many of the body's systems, particularly the brain and nervous system (encephalo-) and muscles (myopathy). In most cases, the signs and symptoms of this disorder appear in childhood following a period of normal development. Early symptoms may include
- Muscle weakness
- Muscle pain
- Recurrent headaches
- Loss of appetite
- Vomiting
- Seizures
- Abdominal pain
- Extreme tiredness (fatigue)
- Difficulty breathing
Physical Examination
Eye
Ear
Extremeties
Neurologic
- Stroke-like episodes beginning before age 40 [6]
- Temporary muscle weakness on one side of the body (hemiparesis)
- Altered consciousness
- Ataxia
- Seizures
- Dementia
Laboratory Findings
Laboratory workup involves assessing serum pyruvic acid, serum lactic acid, cerebrospinal fluid (CSF) pyruvic acid, and CSF lactic acid. An elevation in lactic acid levels, especially during an acute stroke-like episode, is a frequent initial finding. However, lactic acids may be normal in some people and an increased CSF lactic acid level has been shown to be a more reliable indicator of disease.[7] [8]However, systemic metabolic acidosis does not occur.
Imaging Findings
Histopathological Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
References
- ↑ Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP (1984). "Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome". Ann. Neurol. 16 (4): 481–8. doi:10.1002/ana.410160409. PMID 6093682. Unknown parameter
|month=
ignored (help) - ↑ "MELAS - Genetics Home Reference".
- ↑ Hirano M, Pavlakis SG (1994). "Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts". J. Child Neurol. 9 (1): 4–13. PMID 8151079. Unknown parameter
|month=
ignored (help) - ↑ "StatPearls". 2024. PMID 30422554.
- ↑ "StatPearls". 2024. PMID 30422554.
- ↑ Hirano M, Ricci E, Koenigsberger MR; et al. (1992). "Melas: an original case and clinical criteria for diagnosis". Neuromuscul. Disord. 2 (2): 125–35. PMID 1422200.
- ↑ Yamada K, Toribe Y, Yanagihara K, Mano T, Akagi M, Suzuki Y (2012). "Diagnostic accuracy of blood and CSF lactate in identifying children with mitochondrial diseases affecting the central nervous system". Brain Dev. 34 (2): 92–7. doi:10.1016/j.braindev.2011.08.004. PMID 21875773.
- ↑ Magner M, Szentiványi K, Svandová I, Ješina P, Tesařová M, Honzík T; et al. (2011). "Elevated CSF-lactate is a reliable marker of mitochondrial disorders in children even after brief seizures". Eur J Paediatr Neurol. 15 (2): 101–8. doi:10.1016/j.ejpn.2010.10.001. PMID 21075023.